Ovulation suppression for endometriosis for women with subfertility

Background Endometriosis is the presence of endometrial glands or stroma in sites other than the uterine cavity and appears to be an oestrogen-dependent condition. This dependency has prompted the therapeutic use of ovulation suppression agents in an effort to improve subsequent fertility. Objectives To assess the effectiveness of ovulation suppression agents, including danazol, progestins and oral contraceptives, in the treatment of endometriosis-associated subfertility in improving pregnancy outcomes including live births. Search methods We searched the Cochrane Menstrual Disorders and Subfertility Group Specialised Register of trials (February 2009), Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2009), MEDLINE (1966 to February 2009), EMBASE (1980 to February 2009), and reference lists of articles. Selection criteria Randomised trials comparing an ovulation suppression agent with placebo or no treatment, a suppressive agent with danazol, or a gonadotropin-releasing hormone analogue (GnRHa) with oral contraception in women with endometriosis. Data collection and analysis Two review authors independently extracted data and assessed quality. We contacted study authors for additional information. Main results Twenty-five trials were included. Only two studies reported live births. The odds ratios (OR) for pregnancy following ovulation suppression versus placebo or no treatment was 0.97 (95% confidence interval (CI) 0.68 to 1.34, P = 0.8) for all women randomised, and 1.02 (95% CI 0.70 to 1.52, P = 0.82) for subfertile couples only despite the use of a variety of suppression agents. There was no evidence of benefit from the treatment. The common OR for pregnancy following all agents versus danazol was 1.38 (95% CI 1.05 to 1.82, P = 0.02) for all women randomised, and 1.37 (95% CI 0.94 to 1.99, P = 0.10) for subfertile couples only. When GnRHa and danazol were directly compared, the OR was 1.45 (95% CI 1.08 to 1.95, P = 0.01) for all women randomised, and 1.63 (95% CI 1.12 to 2.37, P = 0.01) for subfertile couples only, in favour of GnRHa. No effect was observed for GnRHa compared with oral contraception (OR 0.93, 95% CI 0.41 to 2.12, P = 0.86 for all women randomised; OR 0.83, 95% CI 0.34 to 2.05, P = 0.69 for subfertile couples only). Authors' conclusions There is no evidence of benefit in the use of ovulation suppression in subfertile women with endometriosis who wish to conceive.

[1]  C. Nilsson,et al.  Nafarelin for endometriosis: A large‐scale, danazol‐controlled trial of efficacy and safety, with 1‐year follow‐up , 1992, Fertility and sterility.

[2]  J. Rock,et al.  Zoladex (Goserelin Acetate Implant) in the Treatment of Endometriosis: A Randomized Comparison With Danazol , 1993, Obstetrics and gynecology.

[3]  I. Sargent,et al.  Antiendometrial Antibodies in Endometriosis Measured by an Enzyme-Linked Immunosorbent Assay Before and After Treatment With Danazol and Nafarelin , 1990, Obstetrics and gynecology.

[4]  M. Candiani,et al.  Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III-IV: a randomized controlled trial. , 2001, Human reproduction.

[5]  L. Fedele,et al.  Buserelin acetate versus expectant management in the treatment of infertility associated with minimal or mild endometriosis: a randomized clinical trial. , 1992, American journal of obstetrics and gynecology.

[6]  P. Vandekerckhove,et al.  Ovulation suppression for endometriosis. , 2003, The Cochrane database of systematic reviews.

[7]  J. Collins,et al.  A quantitative overview of controlled trials in endometriosis-associated infertility. , 1993, Fertility and sterility.

[8]  W. Dmowski,et al.  Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. , 1989, Fertility and sterility.

[9]  J. Check,et al.  The importance of laparoscopic coagulation of mild endometriosis in infertile women. , 1987, International journal of fertility.

[10]  J. Sampson,et al.  Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity , 1927 .

[11]  R. Kistner,et al.  Revised American Fertility Society classification of endometriosis: 1985. , 1985, Fertility and sterility.

[12]  C. M. Thomas,et al.  On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol. , 1992, Fertility and sterility.

[13]  L. Fedele,et al.  Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. , 1994, American journal of obstetrics and gynecology.

[14]  M. Seibel,et al.  The effectivenss of danazol on subsequent fertility in minimal endometriosis. , 1982, Fertility and sterility.

[15]  A. Bergqvist,et al.  Effects of triptorelin versus placebo on the symptoms of endometriosis. , 1998, Fertility and sterility.

[16]  M. Soules,et al.  Medical treatment of endometriosis: a comparison of the suppressive effects of danazol and nafarelin on reproductive hormones. , 1991, Fertility and sterility.

[17]  P Sismondi,et al.  A gonadotrophin‐releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis , 1999, British journal of obstetrics and gynaecology.

[18]  M. Candiani,et al.  Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. , 1999, Human reproduction.

[19]  D. Querleu,et al.  Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. , 2002, Fertility and sterility.

[20]  C. Coulam,et al.  Treatment of endometriosis with the GnRH agonist nafarelin acetate. , 1991, International journal of fertility.

[21]  M. Seibel,et al.  Efficacy of danazol treatment for minimal endometriosis in infertile women. A prospective, randomized study. , 1988, The Journal of reproductive medicine.

[22]  L. Fedele,et al.  Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study. , 1993, Fertility and sterility.

[23]  L. Fedele,et al.  Gestrinone versus danazol in the treatment of endometriosis. , 1989, Fertility and sterility.

[24]  P. Vercellini,et al.  Buserelin versus danazol in the treatment of endometriosis-associated infertility. , 1989, American journal of obstetrics and gynecology.

[25]  S. Telimaa Danazol and medroxyprogesterone acetate inefficacious in the treatment of infertility in endometriosis. , 1988, Fertility and sterility.

[26]  K. Seow,et al.  Short-term postoperative GnRH analogue or danazol treatment after conservative surgery for stage III or IV endometriosis before ovarian stimulation: a prospective, randomized study. , 2004, Journal of reproductive medicine.

[27]  D. Bromham,et al.  A multicentre comparative study of gestrinone and danazol in the treatment of endometriosis , 1995 .

[28]  V. Gomel Laparoscopy and hysteroscopy in gynecologic practice , 1986 .

[29]  J. D. Miller,et al.  Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results. , 1992, American journal of obstetrics and gynecology.

[30]  E. Thomas,et al.  Successful treatment of asymptomatic endometriosis: does it benefit infertile women? , 1987, British medical journal.

[31]  J. Puolakka,et al.  Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. , 1987, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[32]  R. Low,et al.  A comparative study of various dosages of danazol in the treatment of endometriosis , 1984, British journal of obstetrics and gynaecology.

[33]  R. Harrison,et al.  Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. , 2000, Fertility and sterility.

[34]  R. Shaw Nafarelin in the treatment of pelvic pain caused by endometriosis. , 1990, American journal of obstetrics and gynecology.

[35]  J. D. Miller,et al.  Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. , 1993, American journal of obstetrics and gynecology.

[36]  J. Rock,et al.  Management of pelvic endometriosis with low-dose danazol. , 1981, Fertility and sterility.

[37]  A. Lemay,et al.  Bone Mass in Endometriosis Patients Treated With GnRH Agonist Implant or Danazol , 1991, Obstetrics and gynecology.

[38]  D. Barlow,et al.  A comparison of nafarelin acetate and danazol in the treatment of endometriosis. , 1990, Fertility and sterility.

[39]  I. Laing,et al.  Influence of danazol and goserelin on insulin and glucagon in non-obese women with endometriosis. , 1990, Acta endocrinologica.

[40]  R. Jansen,et al.  A Comparative Treatment Trial of Endometriosis Using the Gonadotrophin‐releasing Hormone Agonist, Nafarelin, and the Synthetic Steroid, Danazol , 1991, The Australian & New Zealand journal of obstetrics & gynaecology.

[41]  N. Gleicher,et al.  Is endometriosis an autoimmune disease? , 1988, Obstetrics and gynecology.

[42]  D. Apter,et al.  Placebo-controlled comparison of hormonal and biochemical effects of danazol and high-dose medroxyprogesterone acetate. , 1990, European journal of obstetrics, gynecology, and reproductive biology.

[43]  K. Biberoğlu,et al.  Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness. , 1981, American journal of obstetrics and gynecology.

[44]  R. Shaw,et al.  A randomized comparative study of the metabolic effects of two regimens of gestrinone in the treatment of endometriosis. , 1993, Fertility and sterility.

[45]  A. Scommegna,et al.  Variable effects of danazol on endometriosis at 4 low-dose levels. , 1982 .

[46]  D. Illingworth,et al.  Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol. , 1989, American journal of obstetrics and gynecology.

[47]  R. Shaw,et al.  An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Zoladex Endometriosis Study Team. , 1992, Fertility and sterility.

[48]  C. Nilsson,et al.  Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis. , 1989, The Journal of clinical endocrinology and metabolism.

[49]  R. Barbieri,et al.  A randomized double-blind prospective trial of two doses of gestrinone in the treatment of endometriosis. , 1990, Fertility and sterility.

[50]  R. Rolland,et al.  Nafarelin versus danazol in the treatment of endometriosis. , 1990, American journal of obstetrics and gynecology.

[51]  A. Kauppila,et al.  Elevated serum levels of endometrial secretory protein PP14 in patients with advanced endometriosis. Suppression by treatment with danazol and high-dose medroxyprogesterone acetate. , 1989, American journal of obstetrics and gynecology.

[52]  D. Guzick,et al.  Revised endometriosis classification: 1996. , 1997, Fertility and sterility.

[53]  A. Lemay,et al.  Cholesterol fractions and apolipoproteins during endometriosis treatment by a gonadotrophin releasing hormone (GnRH) agonist implant or by danazol , 1991, Clinical endocrinology.

[54]  K. Moghissi,et al.  Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. , 1988, The New England journal of medicine.

[55]  A. C. Rossi,et al.  A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis. , 2008, European journal of obstetrics, gynecology, and reproductive biology.

[56]  C. Bergquist Effects of nafarelin versus danazol on lipids and calcium metabolism. , 1990, American journal of obstetrics and gynecology.